Emerging biomarkers for cancer immunotherapy in melanoma

被引：35

作者：

Axelrod, Margaret L. ^{[1
,2
]}

Johnson, Douglas B. ^{[1
]}

Balko, Justin M. ^{[1
,2
,3
]}

机构：

[1] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA

[2] Vanderbilt Univ, Med Ctr, Canc Biol, Nashville, TN USA

[3] Vanderbilt Univ, Med Ctr, Breast Canc Res Program, Nashville, TN USA

来源：

SEMINARS IN CANCER BIOLOGY | 2018年 / 52卷

关键词：

Melanoma; Biomarker; Checkpoint inhibitor; PD-1; CTLA-4; T-CELL; PD-1; BLOCKADE; MICROSATELLITE INSTABILITY; ANTI-PD-1; THERAPY; CLINICAL-OUTCOMES; PREDICTS RESPONSE; CTLA-4; ADVERSE EVENTS; ASSOCIATION; RESISTANCE;

D O I：

10.1016/j.semcancer.2017.09.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The treatment and prognosis of metastatic melanoma has changed substantially since the advent of novel immune checkpoint inhibitors (ICI), agents that enhance the anti-tumor immune response. Despite the success of these agents, clinically actionable biomarkers to aid patient and regimen selection are lacking. Herein, we summarize and review the evidence for candidate biomarkers of response to ICIs in melanoma. Many of these candidates can be examined as parts of a known molecular pathway of immune response, while others are clinical in nature. Due to the ability of ICIs to illicit dramatic and durable responses, well-validated biomarkers that can be effectively implemented in the clinic will require strong negative predictive values that do not limit patients with who may benefit from ICI therapy.

引用

页码：207 / 215

页数：9

共 67 条

[1] Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports [J].

Abdel-Wahab, Noha ;

Shah, Mohsin ;

Suarez-Almazor, Maria E. .

PLOS ONE, 2016, 11 (07)

[2] Genomic Classification of Cutaneous Melanoma [J].

Akbani, Rehan ;

Akdemir, Kadir C. ;

Aksoy, B. Arman ;

Albert, Monique ;

Ally, Adrian ;

Amin, Samirkumar B. ;

Arachchi, Harindra ;

Arora, Arshi ;

Auman, J. Todd ;

Ayala, Brenda ;

Baboud, Julien ;

Balasundaram, Miruna ;

Balu, Saianand ;

Barnabas, Nandita ;

Bartlett, John ;

Bartlett, Pam ;

Bastian, Boris C. ;

Baylin, Stephen B. ;

Behera, Madhusmita ;

Belyaev, Dmitry ;

Benz, Christopher ;

Bernard, Brady ;

Beroukhim, Rameen ;

Bir, Natalie ;

Black, Aaron D. ;

Bodenheimer, Tom ;

Boice, Lori ;

Boland, Genevieve M. ;

Bono, Riccardo ;

Bootwalla, Moiz S. ;

Bosenberg, Marcus ;

Bowen, Jay ;

Bowlby, Reanne ;

Bristow, Christopher A. ;

Brockway-Lunardi, Laura ;

Brooks, Denise ;

Brzezinski, Jakub ;

Bshara, Wiam ;

Buda, Elizabeth ;

Burns, William R. ;

Butterfield, Yaron S. N. ;

Button, Michael ;

Calderone, Tiffany ;

Cappellini, Giancarlo Antonini ;

Carter, Candace ;

Carter, Scott L. ;

Cherney, Lynn ;

Cherniack, Andrew D. ;

Chevalier, Aaron ;

Chin, Lynda .

CELL, 2015, 161 (07) :1681-1696

[3] Clinical Outcomes in Metastatic Uveal Melanoma Treated With PD-1 and PD-L1 Antibodies [J].

Algazi, Alain P. ;

Tsai, Katy K. ;

Shoushtari, Alexander N. ;

Munhoz, Rodrigo R. ;

Eroglu, Zeynep ;

Piulats, Josep M. ;

Ott, Patrick A. ;

Johnson, Douglas B. ;

Hwang, Jimmy ;

Daud, Adil I. ;

Sosman, Jeffrey A. ;

Carvajal, Richard D. ;

Chmielowski, Bartosz ;

Postow, Michael A. ;

Weber, Jeffrey S. ;

Sullivan, Ryan J. .

CANCER, 2016, 122 (21) :3344-3353

[4] Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC). [J].

Bendell, Johanna C. ;

Kim, Tae Won ;

Goh, Boon C. ;

Wallin, Jeffrey ;

Oh, Do-Youn ;

Han, Sae-Won ;

Lee, Carrie B. ;

Hellmann, Matthew David ;

Desai, Jayesh ;

Lewin, Jeremy Howard ;

Solomon, Benjamin J. ;

Chow, Laura Quan Man ;

Miller, Wilson H. ;

Gainor, Justin F. ;

Flaherty, Keith ;

Infante, Jeffrey R. ;

Das-Thakur, Meghna ;

Foster, Paul ;

Cha, Edward ;

Bang, Yung-Jue .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

[5]

Cabel L, 2017, ANN ONCOL

[6] Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1 [J].

Champiat, Stephane ;

Dercle, Laurent ;

Ammari, Samy ;

Massard, Christophe ;

Hollebecque, Antoine ;

Postel-Vinay, Sophie ;

Chaput, Nathalie ;

Eggermont, Alexander ;

Marabelle, Aurelien ;

Soria, Jean-Charles ;

Ferte, Charles .

CLINICAL CANCER RESEARCH, 2017, 23 (08) :1920-1928

[7] Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma [J].

Daud, Adil I. ;

Loo, Kimberly ;

Pauli, Mariela L. ;

Sanchez-Rodriguez, Robert ;

Sandoval, Priscila Munoz ;

Taravati, Keyon ;

Tsai, Katy ;

Nosrati, Adi ;

Nardo, Lorenzo ;

Alvarado, Michael D. ;

Algazi, Alain P. ;

Pampaloni, Miguel H. ;

Lobach, Iryna V. ;

Hwang, Jimmy ;

Pierce, Robert H. ;

Gratz, Iris K. ;

Krummel, Matthew F. ;

Rosenblum, Michael D. .

JOURNAL OF CLINICAL INVESTIGATION, 2016, 126 (09) :3447-3452

[8] Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma [J].

Diem, S. ;

Kasenda, B. ;

Spain, L. ;

Martin-Liberal, J. ;

Marconcini, R. ;

Gore, M. ;

Larkin, J. .

BRITISH JOURNAL OF CANCER, 2016, 114 (03) :256-261

[9] Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis [J].

Dubin, Krista ;

Callahan, Margaret K. ;

Ren, Boyu ;

Khanin, Raya ;

Viale, Agnes ;

Ling, Lilan ;

No, Daniel ;

Gobourne, Asia ;

Littmann, Eric ;

Huttenhower, Curtis ;

Pamer, Eric G. ;

Wolchok, Jedd D. .

NATURE COMMUNICATIONS, 2016, 7

[10] Microsatellite Instability as a Biomarker for PD-1 Blockade [J].

Dudley, Jonathan C. ;

Lin, Ming-Tseh ;

Le, Dung T. ;

Eshleman, James R. .

CLINICAL CANCER RESEARCH, 2016, 22 (04) :813-820

← 1 2 3 4 5 6 7 →